Somatic mutations and deletions of PARK2, an E3-ubiquitin ligase involved in degradation of several target proteins including the cell cycle modulator cyclin E, have been reported in different tumor types [44], whereas germinal mutations in PARK2 are linked to PD. This evidence concerns the gene PRKN and neoplasm.